Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen(Moores Cancer Center), Signe Friesland, Kelvin Chan(Occupational Cancer Research Centre), Pingye Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jessica R. Bauman, Nicolas Mach(University of Geneva), Barbara Burtness(Yale University), Victoria Bray, Jean‐Pierre Delord, Mirelis Acosta-Rivera, Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anna Alyasova, Morteza Aghmesheh(New South Wales Department of Health), Myung‐Ju Ahn(Sungkyunkwan University), Eduardas Aleknavičius, Laurence Digue, Mary J. Fidler, Ranee Mehra(University of Maryland, Baltimore), Lisa Licitra(University of Milan), Mario Airoldi, Charlotte Dupuis, Christophe Le Tourneau(Institut Curie), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Douglas R. Adkins(Washington University in St. Louis), José Dinis(IPO Porto), Tibor Csőszi, Salah Almokadem, Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Alain P. Algazi(University of California, San Francisco), Jan Paul de Boer, Ainara Soria(Hospital Universitario Ramón y Cajal), Martin Förster, Marco Benasso, Yousuf Al-Farhat, Terrence P. Cescon, Alfonso Berrocal, Andreas Dietz(Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde), Mererid Evans(Velindre NHS Trust), Bruno Chauffert(Centre Hospitalier de Saint-Quentin), József Erfán, Francesco Caponigro, Arvind Chaudhry, Jonathan D. Cheng(Princeton University), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc)
Cited by 1,690
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k